Related Experiment Video

Updated: Aug 13, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
13:10

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

Tirofiban in acute coronary syndromes

Alberto Menozzi1, Piera Angelica Merlini, Diego Ardissino

  • 1Division of Cardiology, Maggiore Hospital, University of Parma, Parma, Italy. almenozzi@ao.pr.it

Expert Review of Cardiovascular Therapy
|April 28, 2005
PubMed

Insights

Tirofiban, a glycoprotein IIb/IIIa inhibitor, effectively treats acute coronary syndromes, particularly non-ST-segment elevation myocardial infarction. Early administration with aggressive revascularization improves outcomes for high-risk patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Acute coronary syndromes (ACS) are a significant cause of mortality.
  • Platelet-rich thrombi are central to ACS pathogenesis.
  • Glycoprotein IIb/IIIa receptors are crucial for platelet aggregation.

Purpose of the Study:

  • To review the clinical use and efficacy of tirofiban in ACS.
  • To discuss tirofiban's benefits in various treatment strategies and drug combinations.
  • To emphasize the role of early tirofiban administration in high-risk ACS.

Main Methods:

  • Review of clinical trial data on tirofiban in ACS.
  • Analysis of tirofiban's efficacy in non-ST-segment elevation ACS.
  • Evaluation of tirofiban's use in percutaneous coronary angioplasty.

Main Results:

  • Tirofiban is clinically effective with a low adverse event rate in non-ST-segment elevation ACS.
  • Tirofiban has demonstrated efficacy in managing ACS and during percutaneous coronary angioplasty.
  • Early, upstream tirofiban combined with early revascularization is beneficial for high-risk ACS.

Conclusions:

  • Tirofiban is a valuable parenteral glycoprotein IIb/IIIa inhibitor for ACS management.
  • Its efficacy and safety profile support its use in specific ACS patient populations.
  • Optimizing tirofiban's role in treatment strategies can improve patient outcomes.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...